Renaissance Technologies LLC Invests $778,000 in Lumexa Imaging Holdings, Inc. $LMRI

Renaissance Technologies LLC purchased a new position in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 90,423 shares of the company’s stock, valued at approximately $778,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Monashee Investment Management LLC purchased a new stake in shares of Lumexa Imaging in the fourth quarter worth approximately $2,775,000. Seven Grand Managers LLC purchased a new position in Lumexa Imaging during the 4th quarter valued at $11,942,000. Element Capital Management LLC bought a new position in Lumexa Imaging in the 4th quarter valued at $1,616,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Lumexa Imaging in the 4th quarter valued at $27,750,000. Finally, Hunter Associates Investment Management LLC purchased a new stake in Lumexa Imaging in the first quarter worth $1,231,000.

Insider Activity

In other Lumexa Imaging news, Director Brett Brodnax purchased 35,000 shares of Lumexa Imaging stock in a transaction dated Tuesday, May 19th. The shares were acquired at an average cost of $7.25 per share, with a total value of $253,750.00. Following the completion of the transaction, the director owned 62,027 shares in the company, valued at approximately $449,695.75. This trade represents a 129.50% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

LMRI has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft set a $16.00 target price on Lumexa Imaging in a research report on Thursday. Weiss Ratings raised shares of Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research note on Thursday, June 25th. Barclays decreased their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a report on Wednesday, May 20th. Finally, Wall Street Zen raised shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Lumexa Imaging Trading Down 1.5%

NASDAQ LMRI opened at $12.02 on Friday. Lumexa Imaging Holdings, Inc. has a 52 week low of $6.45 and a 52 week high of $19.45. The company has a 50 day moving average price of $10.85 and a 200 day moving average price of $10.91. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.43. The firm has a market cap of $1.15 billion and a PE ratio of -20.37.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).